Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

NASDAQ:CARA

Overview | Financials
Company Name Cara Therapeutics, Inc.
Symbol CARA
Currency USD
Price 5.125
Market Cap 23,427,554
Dividend Yield 0%
52-week-range 2.712 - 11.52
Industry Biotechnology
Sector Healthcare
CEO Mr. Christopher A. Posner
Website https://www.caratherapeutics.com

An error occurred while fetching data.

About Cara Therapeutics, Inc.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The

Related Stocks

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

13.21 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

4.95 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.13 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

7.44 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

3.46 USD

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

28.36 USD

Immatics N.V. logo

Immatics N.V.

IMTX

4.45 USD

Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

3.67 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

6.61 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

19.61 USD

Financials

Numbers are in millions USD

Numbers are in millions USD